Viewing Study NCT06420154



Ignite Creation Date: 2024-05-19 @ 5:35 PM
Last Modification Date: 2024-10-26 @ 3:30 PM
Study NCT ID: NCT06420154
Status: NOT_YET_RECRUITING
Last Update Posted: 2024-05-17
First Post: 2024-05-14

Brief Title: The Safety and Efficacy of Anti-CD19 CAR-T Cells in Patients With RelapsedRefractory Autoimmune Diseases
Sponsor: First Affiliated Hospital of Wenzhou Medical University
Organization: First Affiliated Hospital of Wenzhou Medical University

Study Overview

Official Title: An Exploratory Clinical Study to Evaluating the Safety and Efficacy of Infusiing Anti-CD19-CAR-T Cells Injection Anti-CD19-CAR-T Cells in Patients With RelapsedRefractory Autoimmune Diseases
Status: NOT_YET_RECRUITING
Status Verified Date: 2024-05
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: This is an investigator-initiated trial to evaluate the safety and efficacy of anti- CD19-CAR-T cells in the relapse or refractory autoimmune diseases
Detailed Description: This is an investigator-initiated trial to evaluate the safety and efficacy of anti- CD19-CAR-T cells in the relapse or refractory autoimmune diseases

Study intervention consists of a single infusion of CAR-transduced autologous T cells administered intravenously after a lymphodepleting therapy regimen consisting of fludarabine and cyclophosphamide

Interim analysis will be performed when the last participant finishes the visit of 12 weeks after CAR-T cells infusion

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None